Seeking Alpha

The FDA grants a priority review designation to Bristol-Myers Squibb (BMY) and AstraZeneca (AZN)...

The FDA grants a priority review designation to Bristol-Myers Squibb (BMY) and AstraZeneca (AZN) for their metreleptin treatment for disorders associated with lipodystrophy (LD), a very rare disease in which sufferers experience a loss of fat tissue in important areas, especially under the skin. The fat instead accumulates where it shouldn't, such as in muscles and the liver, and can cause severe insulin resistance, diabetes and high levels of triglycerides. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)